NCT02404311: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 411 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02404311 |
|---|---|
| Title | A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected Adults at Low Risk of HIV Infection |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 2, 2015 |
| Completion date | Aug. 7, 2018 |
| Required reporting date | Aug. 7, 2019, midnight |
| Actual reporting date | Sept. 21, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 411 |